Platelet BioGenesis
Pioneering the future of medicine with breakthrough technology for producing donor-independent human platelets from stem cells
Pioneering the future of medicine with breakthrough technology for producing donor-independent human platelets from stem cells
Platelet BioGenesis, founded in 2014, is a biotechnology startup pioneering the future of medicine with breakthrough technology for producing donor-independent human platelets from stem cells. Specializing in biotechnology, platelets, and drug discovery, the company has developed a unique approach to generate donor-independent human platelets from human induced pluripotent stem cells. In November 2021, the company secured a significant $75.50M Series B investment. The investors contributing to this round include Qiming Venture Partners, K2 HealthVentures, Symbiosis LLC, Ziff Capital Partners, Oxford Finance LLC. Platelet BioGenesis is contributing to advancements in biotechnology and life sciences with its innovative approach to platelet production.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $75.50M | 5 |
|
04 Nov 2021 |
| Grant | $2.30M | 1 | Medical Technology Enterprise Consortium | 16 Dec 2019 |
| Series A | $26.00M | 4 |
|
09 Sep 2019 |
| Series A | $11.36M | - | 05 Jun 2019 | |
| Series A | Unknown | 1 |
|
31 May 2019 |
No recent news or press coverage available for Platelet BioGenesis.
We care about your data, and we'd love to use cookies make your experience better.
